Overview

A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain

Status:
Completed

Trial end date:
2011-09-08

Target enrollment:

Participant gender:

Summary

MNTX 3201 is a Phase 3, international, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of oral MNTX for the treatment of opioid induced constipation in participants with chronic, non-malignant pain.

Phase:

Phase 3

Details

Lead Sponsor:

Bausch Health Americas, Inc.
Valeant Pharmaceuticals International, Inc.

Collaborator:

Progenics Pharmaceuticals, Inc.

Treatments:

Analgesics, Opioid
Bromides
Methylnaltrexone
Naltrexone